$OMER

Cable Thomas J. sold $87K of OMER

Cable Thomas J. sold 7,500 shares of OMEROS CORP (OMER) at $11.61 on 2026-05-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cable Thomas J.
Published May 27, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The disclosure provides transparency on director selling activity but does not introduce new information about OMEROS operations, financial performance, or external catalysts.

02

Market read

This is primarily a sentiment/positioning datapoint for OMER, with limited fundamental implications.

03

What to watch

Traders may overreact to insider selling; the key missing detail is whether there were concurrent buys or other insider activity around the same period.

Relevance 2/10Novelty 3/10Timing: Filed 2026-05-27, transaction dated 2026-05-22.

Background

The article is an SEC Form 4 insider transaction disclosure for OMEROS Corp.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

OMEROS director Cable Thomas J. sold 7,500 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a stated 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/contract events.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • OMEROS CORP

    Company whose director insider sale is disclosed on Form 4.

  • Cable Thomas J.

    Director who sold 7,500 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMERHighAI 8/10

Omeros (OMER) Q2 2026 Earnings Call Transcript

Omeros (OMER) reported Q2 2026 earnings with Yartemlia gross sales at $32.2M, up 190% from Q1. Net income was $13.2M, including a $11.5M non-cash gain. The company reduced debt by 43% and generated $4.1M in operating cash flow. However, the EMA's committee issued a negative opinion on Yartemlia's marketing authorization application for TA-TMA.

$OMERMed

Omeros Corporation Q2 2026 Earnings Call Summary

Omeros reported Q2 2026 progress for Yartemlia, citing 188% quarter-over-quarter net sales growth and $4.1 million positive operating cash flow. Management said adult transplant centers now drive about 75% of sales and formulary approval is 55% to 60%. It also discussed cash flow positivity by mid-2027, repurchases, and regulatory items including a July 1 J-code and Oct. 1 NTAP.

$OMERHighAI 9/10

Why is Omeros stock surging today?

Omeros (OMER) shares rose about 17% in pre-open after the company reported Q2 2026 results. Adjusted EPS was $0.02 versus a consensus $0.25 loss, and revenue was $28.5M versus $12.67M expected. YARTEMLEA sales were $32.2M gross, and Omeros reported GAAP net income of $13.2M and first positive operating cash flow.

$OMERMed

OMEROS CORP (OMER): Results of Operations and Financial Condition

OMEROS CORP (OMER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Omeros Corporation Reports Second Quarter 2026 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 12, 2026 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second q

$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.